BioTuesdays
Cue Biopharma Logo
Markets

BTIG starts Cue Biopharma at buy; PT $26

BTIG launched coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $26 price target. The stock closed at $15.51 on Jan. 27. Cue Biopharma exploits signals naturally provided by dendritic cells (DCs) to...

January 28, 2020
CollPlant
Markets

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

January 27, 2020
Itamar Medical
Markets

AGP ups Itamar Medical PT to $19.50 from $15.50

Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $19.50 from $15.50, reflecting preliminary fourth quarter revenue results, 2020 guidance and a recent meeting with the company’s...

January 22, 2020
ArTara Therapeutics
Markets

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

January 22, 2020
Protech Home Medical
Markets

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...

January 22, 2020
Capricor Therapeutics Logo
Markets

HCW lowers Capricor Therapeutics PT to $9

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...

January 21, 2020
Accuray
Markets

BTIG ups Accuray to buy; PT $9.50

BTIG upgraded Accuray (NASDAQ:ARAY) to “buy” from “neutral,” with a price target of $9.50. The stock closed at $3.28 on Jan. 17. Last week, Accuray announced a compound annual growth rate revenue outlook of 8% to 12%...

January 21, 2020
Mersana Therapeutics Logo
Markets

HCW ups Mersana Therapeutics PT to $12 from $7

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s XMT-1536 drug candidate...

January 21, 2020
Acasti Pharma
Markets

Mackie puts Acasti Pharma under review; removes PT

Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...

January 13, 2020
Millendo Therapeutics
Markets

Roth starts Millendo Therapeutics at buy; PT $35

Roth Capital Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $35 price target. The stock closed at $7.63 on Jan. 9. Millendo is a clinical-stage company focusing on the...

January 10, 2020
Markets

SVB Leerink starts Organogenesis at OP; PT $9

SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...

January 10, 2020
Profound Medical Logo
Markets

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

January 10, 2020
Cassava Sciences
Markets

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

January 10, 2020
iRhythm Technologies
Markets

WB starts iRhythm Technologies at OP

William Blair launched coverage of iRhythm Technologies (NASDAQ:IRTC) with an “outperform” rating, calling the company’s digital health platform “market disrupting.” The stock closed at $71.76, up $1.12, on Jan. 9...

January 10, 2020
Xenon Pharma
Markets

WB starts Xenon Pharma at OP; estimated fair value $27

William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...

January 8, 2020
X4 Pharma
Markets

HCW starts X4 Pharma at buy; PT $22

H.C. Wainwright launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $22 price target. The stock closed at $10.39 on Jan. 6. The company’s lead product candidate, mavorixafor, is a potential...

January 7, 2020
Crinetics Logo
Markets

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

December 23, 2019
Valeritas Holdings Logo
Markets

BTIG cuts Valeritas Holdings to neutral; removes PT

BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...

December 23, 2019
Markets

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

December 23, 2019
Ocugen
Markets

HCW starts Ocugen at buy; PT $1.25

H.C. Wainwright launched coverage of Ocugen (NASDAQ:OCGN) with a “buy” rating and price target of $1.25. The stock closed at 36 cents on Dec. 19. Ocugen is developing therapies for rare and underserved eye diseases and...

December 20, 2019